Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
Chemokine CXCL13 as a Marker of Disease Activity in Systemic Lupus Erythematosus
1 other identifier
observational
86
0 countries
N/A
Brief Summary
Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive antibodies.The chemokine CXC ligand 13 protein (CXCL13), also known as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), CXCL13 serum levels were correlated with disease activity using the SLE Disease Activity Index (SLEDAI) and to lupus nephritis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2019
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 22, 2018
CompletedFirst Posted
Study publicly available on registry
November 26, 2018
CompletedStudy Start
First participant enrolled
March 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedJanuary 29, 2019
November 1, 2018
1 year
November 22, 2018
January 27, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
to measure the level of cxcl13 in SLE
to differentiate the level of (cxcl13) between healthy individuals and patients with SLE
Baseline
Study Arms (2)
cases
patients with SLE
controls
Healthy people
Interventions
Eligibility Criteria
two groups: 46 patients with SLE 40 healthy people
You may qualify if:
- SLE patients diagnosed according to ACR
You may not qualify if:
- patient with other autoimmune diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Ahmadpoor P, Dalili N, Rostami M. An update on pathogenesis of systemic lupus erythematosus. Iran J Kidney Dis. 2014 May;8(3):171-84.
PMID: 24878938BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assuit lecturer
Study Record Dates
First Submitted
November 22, 2018
First Posted
November 26, 2018
Study Start
March 1, 2019
Primary Completion
March 1, 2020
Study Completion
December 1, 2020
Last Updated
January 29, 2019
Record last verified: 2018-11
Data Sharing
- IPD Sharing
- Will not share